

MGA Founder Joan Stackhouse passes

On Wednesday March 1, 2023 our founder, Joan Stackhouse passed away at age 91 in Pasadena, CA.

We find it fitting that she passed away the first day of Women's Month. A trail blazing lady she was, paving the way and the foundation from her career as a nurse, her life as a mom, sister, wife, artist, a true connector and our founder.

You may recall her husband Rev. Stackhouse and his wife Joan founded the MGA in 1960 as they landed in Kansas City post missionary work in West Africa. Joan had been diagnosed with myasthenia gravis a year before and they found there was little support. Rev. Stackhouse served as a part of Presbyterian Church for 5 years prior to moving to the East Coast. During those 5 years, the Stackhouses built the foundation for the MGA. The Stackhouses retired to Pasadena over 25 years ago.

A funeral was held for Joan on April 15, 2023 in Pasadena. We are grateful for the work that Rev. Stackhouse and Joan did and are thinking of their family during this difficult time.



Longtime Board Member Lisa Sackuvich retires



Speaking of dynamic women, longtime Board Member, Lisa Sackuvich has announced her retirement from our Board of Directors.

Lisa started on the Board of Directors over 30 years ago. Her original introduction was being a part of the auction committee. She then went on with a group of other nurses to develop a half day continuing educational program for nurses at the old Baptist Medical Center.

Lisa has worn many other hats as well as a part of her tenure on the board. From President to Secretary Lisa stated, "I have many wonderful memories of fundraising and educational events. It was truly an honor to serve the MGA. The treatment advances and treatment options now available to people with Myasthenia Gravis, is so promising."

Lisa sold her company ARJ Infusion Services in December 2021 to Promptcare and plans to put her feet up a little more in retirement.

The MGA is forever grateful for the contributions Lisa has made through the years. Her legacy has been stamped on our organization for years to come. Her leadership will be missed. Congratulations Lisa!



The latest at the MYASTHENIA GRAVIS ASSOCIATION

Research for MG donation made to KU

The MGA was able to make a \$12,000 donation to research for myasthenia gravis (MG) at the University of Kansas Medical Center at the end of 2022. On page 4 you'll learn more about KU's commitment to learning more about the COVID-19 impact amongst patients. In addition, Dr. Farmakidis, is wrapping up research on telemedicine and patients with MG. The continued collaboration between KU and the MGA ensures that we are working to bridge the gap between patients and state of the art discoveries with myasthenia gravis.



MGA celebrates National Volunteer Appreciation Month

The MGA appreciates the opportunity to showcase its volunteers during not only during April for Volunteer Appreciation Month but throughout the entire year. A huge thank you to all of our volunteers who spend a lot of time on their "feet" and helping us cover ground to touch and support patients and the community. We are also grateful for our Trivia Committee and our MGA Triple Crown Showdown 5K Committee which work tirelessly behind the scenes on behalf of the MGA.





MGA STAFF

Executive Director

Allison Foss

Community Program

Coordinator

McKenna Fulton

EXECUTIVE BOARD

President

Michael Eagan

Vice President

Brodie Beck

Secretary

Stephanie Hubers

Treasurer

Derek Haverkamp

BOARD MEMBERS

Joe Bant

Jacquelyn Carroll, CMP

LaDonna Diller

Al Dimmitt

Lyndsey Fliehs

Graham Naasz, DDS

Mamatha Pasnoor, MD,
FAAN

Tom Vansaghi, PhD

CONTACT

816-256-4100

info@mgakc.org

A Message from Allison



A few weeks ago, as I was on the way to our printer prior to heading into the office, I dropped by a stand alone post office mailbox to drop in some mail. Approaching the box was another peer living in the area with myasthenia gravis.

We greeted each other and chatted for a few moments.

We talked about how we were each feeling and what our treatments were to date. As I drove away, I couldn't help but smile and think about the community we've created.

Had you asked me in middle school about myasthenia gravis, I probably would have mumbled some answer to you and pretended like it didn't exist. I likely would have done that in high school too. But here we are some 25+ (yikes!) years later, and myasthenia gravis is part of my everyday vocabulary.

Our hope is that we can help you become as comfortable and find a place in the community where you can share your journey, get support, make friends and recognize you aren't alone. We continue to work to vary content and settings so there are more options for people. If you have suggestions for our community, please send them our way.

Wherever you are on your journey, please know you aren't alone and we'd love to walk alongside you.

In Hope & Gratitude,

Allison K. Foss | Executive Director |
allisonfoss@mgakc.org

Inside this Issue

- Page 4** COVID-19 Survey
- Page 4** MG PRIDE
- Page 6** Around the MGA
- Page 7** Clinical Trial Updates
- Page 9** Clinical Trial Updates continued
- Page 10-11** Support Group Updates
- Page 12** Virtual Monthly Meet Ups
- Page 14** Membership Donations

Submissions

Want to share your MG story or have a topic you would like to see covered? Email Allison at allisonfoss@mgakc.org

Follow Us



University of Kansas Neuromuscular Team to study impact of COVID-19 on patients with myasthenia gravis

Written by Swathy Chandrashekhar, MD




Autoimmune myasthenia gravis (MG) is a rare disease manifested by fatigable neuromuscular weakness of eye, limb, respiratory and bulbar (speaking, swallowing, chewing) muscles.

With the onset of the COVID-19 pandemic, there is an ongoing effort to understand the effect of infection in MG patients. MG patients form a vulnerable group during a pandemic such as COVID-19 and are at high risk for poor outcomes due to several reasons - immunocompromised state from MG treatments, pre-existent respiratory muscle and swallowing/throat muscle weakness, lower vaccine efficacy while on immunosuppressants, and the tendency of some COVID-19 treatments such as hydroxychloroquine to worsen MG.

The course of COVID-19 infection in MG patients is variable. Currently published literature demonstrates a bias towards poor outcomes and an incomplete understanding of the true risks and modifiers of COVID-19 in this population, thus highlighting an important knowledge gap.

We will conduct a cross-sectional survey study of patients with myasthenia gravis. Patients with myasthenia gravis (seropositive and seronegative), > 18 years of age, or caregivers answering on the patients' behalf will be included. The survey will be distributed through Myasthenia Gravis Association's mailing list and survey responses will be collected over 3 months. We anticipate that analysis of the data and production of scientific reports will occur over the following 9 months.



The aims of this study will be to assess whether specific factors pertaining to MG disease characteristics and vaccination status are associated with risk of developing COVID-19 infection, and to evaluate outcomes of COVID-19 infection in MG patients. We will also explore if the occurrence and frequency of long-haul COVID is increased in patients with MG.

This study will add to the growing body of knowledge regarding COVID-19 infection in MG patients and help improve our understanding of the true spectrum of outcomes. The results will help delineate risk factors and modifiers to provide evidence-

MG Pride virtual group forming

One of the silver linings of COVID-19 was the discovery of the virtual option. Throughout the past three years we have been able to establish some amazing virtual support groups. Come June 2023, we will be rolling out our newest group, the MG Pride Group. We feel the timing is perfect for the roll out with June being MG Awareness Month as well as Pride Month. This group will be specific to those who identify in the LGBTQ community and led by volunteer, Bryan Bosch. The first session will meet Tuesday June 6th at 7pm. For more information email Bryan at btbosch@gmail.com.





REGISTER TODAY
5th Annual MGA Snowflake Shuffle 0.1K
10:30am | Saturday June 10, 2023

Linwood Recreation Center, Wichita, KS
Register at
www.mgac.org/events-1.html

Patients registration FREE!
Lunch | Kona Ice Truck | Crafts | Industry
Vendors | Photo Ops

For individuals with generalized myasthenia gravis (gMG) finding the strength to complete tasks in your daily life can seem impossible at times. The FLEX Study is investigating a drug called batoclimab for adults living with gMG to manage their symptoms. The second period of this research study may provide the opportunity for participants to self-administer the injectable study drug.

In this clinical research study, doctors want to evaluate the investigational drug to placebo, which looks like the investigational drug, but contains no active medication. The investigational drug has not been approved for the treatment of generalized myasthenia gravis or any other disease. It is considered experimental and can only be given to patients in clinical research studies. The results of this clinical research study will provide more information about batoclimab and its effect on mild to severe generalized myasthenia gravis.

Who is eligible to participate in this clinical research study?

You may be eligible to participate if you:

- Are 18 years of age or older
- Have been diagnosed with mild to severe generalized myasthenia gravis (gMG)
- Have been treated or are currently being treated with medication for gMG
- Meet additional study criteria.
- Study staff will determine eligibility based on additional study criteria



FLEX

To learn more about the clinical research study and to see if you may qualify, please visit our website at www.flexMGtrial.com



Wichita members raise awareness at Wichita State University Wellness Expo

Members of the Wichita area support group, spearheaded by group leaders, Dana and Larry Paxson, gathered at Wichita State University on Wednesday March 1, 2023 for the WSU Annual Wellness Expo. A variety of vendors participated showcasing their cause to attendees. Thank you to all who came out and helped share about myasthenia gravis and raise awareness.



Around the MGA

It's been a busy start to 2023 and we thought we'd give you a quick glimpse of some of the things we've been up to! Don't forget to follow us on social media to stay up to date!



The MGA was honored to be a part of Catalyst Pharmaceuticals visit to ring the Nasdaq closing bell on Rare Disease Day on 2.28.23.



Groups met in Northwest Arkansas (above) and Eastern Jackson County, MO for our Eastsiders Lunch



We kicked off our Central Arkansas Support Group in March.



A Valentine's Day fundraiser was held at Kendra Scott on the Country Club Plaza in Kansas City, MO in conjunction with Sweet Kiss Brigadeiro owned by Jessica Harris, a patient with MG.



nufactor[®]
A SPECIALTY INFUSION COMPANY

Making a difference one patient at a time

Immune Globulin • Factor • Infiximab



Scan code to visit us
at nufactor.com

(800) 323-6832 | nufactor.com



Nufactor Specialty Pharmacy has
earned The Joint Commission Gold
Seal of Approval

Myasthenia Gravis Clinical Trial Updates

University of Kansas Medical Center

MOM-M281-011 ClinicalTrials.gov identifier: NCT04951622

PI: Dr. Farmakidis

Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Experimental: Nipocalimab Double-blind Placebo-controlled Phase:

Participants will receive nipocalimab intravenous (IV) infusions once every 2 weeks (q2w) up to 24 weeks during double-blind placebo-controlled phase.

Placebo Comparator: Placebo Double-blind Placebo-controlled Phase:

Participants will receive matching placebo of nipocalimab IV infusion q2w up to 24 weeks during double-blind placebo-controlled phase.

Open-label Extension (OLE) Phase:

Participants who complete the double-blind placebo-controlled phase will enter the OLE phase and continue to receive nipocalimab q2w IV infusion from OLE Day 1 to 24 weeks.

Participants who are stable on the q2w dosing regimen can be transitioned to a dosing regimen every 4 weeks (q4w) during OLE phase.

For more information contact: Ali Ciersdorff aciersdorff@kumc.edu

Viela Bio ClinicalTrials.gov identifier: NCT04524273

PI: Dr. Pasnoor

A Randomized, Double-blind, Multicenter, Placebo-controlled Phase 3 Study With Open-label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults With Myasthenia Gravis

Experimental: Inebilizumab, (AChR-Ab+) MG

Participants will receive inebilizumab administered intravenously (IV) on Days 1, 15, and 183 of the randomized controlled period.

During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183.

Placebo Comparator: Placebo, (AChR-Ab+) MG

Participants will receive placebo administered IV on Days 1 and 15 and on Day 183 of the randomized controlled period.

During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183.

Experimental: Inebilizumab, (MuSK-Ab+) MG

Participants will receive inebilizumab administered IV on Days 1 and 15 of the randomized controlled period.

During the open-label period, participants will receive inebilizumab administered IV on Days 1 and 183

Placebo Comparator: Placebo, (MuSK-Ab+) MG

Participants will receive placebo administered IV on Days 1 and 15 of the randomized controlled period.

During the open label period, participants will receive inebilizumab administered IV on Days 1, 15 and 183

For more information contact: Lilli Saavedra lsaavedra2@kumc.edu

Janssen ClinicalTrials.gov Identifier: NCT05265273

PI: Dr. Statland

An Open-Label Uncontrolled Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Experimental: Nipocalimab

Participants aged 2 to less than [$<$] 18 years of age will receive nipocalimab once every two weeks for 24 weeks. After Week 24, all participants will have the option to enroll in long term extension (LTE).

Nipocalimab will be administered as an IV infusion

Total enrollment: 12 participants

For more information contact: Katie Lillig kjennens2@kumc.edu

Cabaletta Bio ClinicalTrials.gov identifier: NCT05451212

PI: Dr. Dimachkie

A Phase 1, Open-label, Safety and Dose-finding Study of Autologous Muscle-specific Tyrosine Kinase Chimeric Autoantibody Receptor T Cells (MuSK-CAART) in Subjects With Anti-MuSK-antibody-positive **Myasthenia Gravis**

Experimental: MuSK-CAART

Cohort A: Infusion of MuSK-CAART at various dose levels with or without pre-treatment (6 groups planned).

Cohort B: Infusion of MuSK-CAART at the dose regimen selected from Part A

Total: 24 patients

For more information contact:

Andrew Heim aheim2@kumc.edu



Myasthenia Gravis Clinical Trial Updates

Immunovant MG **ClinicalTrials.gov Identifier: NCT05403541** **PI: Dr. Pasnoor A**
Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)

Experimental: Batoclimab

Period 1 arms:

Batoclimab 680 mg SC weekly

Batoclimab 340 mg SC weekly

Matching Placebo SC

Period 2 arms:

Batoclimab 340 mg SC weekly

Batoclimab 340 mg SC bi-weekly

Matching Placebo SC

Total enrollment: 210 participants

For more information: Nick Staudenmier nstaudenmier@kumc.edu

ALXN1720 – MG **ClinicalTrials.gov Identifier: NTC** **PI: Dr. Dimackie**
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Experimental: ALXN1720

Participants will receive a weight-based maintenance treatment with ALXN1720 on Day 1, followed by weight-based maintenance treatment of ALXN1720 on Week 1 (Day 8) and once every week (Q1W) thereafter for a total of 26 weeks. Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 96 weeks.

Placebo Comparator: Placebo

Participants will receive placebo during the 26-week RCT period, after which they will enter the OLE period of the study and receive ALXN1720.

Total Enrollment: 254 participants

For more information:

Nick Staudenmier nstaudenmier@kumc.edu

Cartesian **ClinicalTrials.gov Identifier: NCT04146051** **PI: Dr. Pasnoor**
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized **Myasthenia Gravis** (MG)

Phase 2 Trial

Experimental: Autologous T-cells expressing a chimeric antigen receptor directed to BCMA (Descartes-08)

Experimental: Phase 1b Dose-Escalation

Intervention: Descartes-08

Experimental: Phase IIa Expansion

Intervention: Descartes-08

Placebo Comparator: Phase IIb Randomized Control Trial

Intervention: Descartes-08

Total enrollment: 30 participants

For more information contact:

Ali Ciersdorff aciersdorff@kumc.edu

Recruiting for children

Argenx ClinicalTrials.gov Identifier: NCT05374590
Evaluating Long-term Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
A Long-term, Single-Arm, Open-label, Multicenter, Follow-on Trial of ARGX-113-2006 to Evaluate Safety of **Efgartigimod** Administered Intravenously in Children With Generalized **Myasthenia Gravis**

The Skinny on MGA Support Groups

COVID-19 POLICY

COVID continues to plague many of our service areas, thus; the board has put a policy in place to protect the health and safety of our community. The following policy reflects our current decision-making process on in-person programming:

In areas where there is a high level of COVID-19 transmission per the CDC, in-person support group meetings will be suspended until the risk level returns to low or medium. The MGA will try to make decisions a week in advance when able. Please check the calendar online and your email for any updates.

Central Arkansas Group

Next Meeting— June 15, 2023

5:30-7:00 PM | Fletcher Library, 823 N. Buchanan St, Little Rock AR 72205

Open to patients, caregivers & providers

RSVP: info@mgakc.org

Coffee with a Coordinator— St. Louis

Next Meeting— April 27, 2023

Monthly | 10:30-11:30 AM | St. Louis Bread Company, 10221 Manchester Rd, Kirkwood, MO

Coffee is Dutch treat | Open to patients, caregivers & providers

RSVP: info@mgakc.org

Eastsiders Lunch Bunch

Next Meeting— May 3, 2023

1st Wednesday of the month | 11:30 AM-1:30 PM | Agape House 312 SW 19th Terrace Street, Blue Springs, MO

Bring your own lunch unless otherwise noted | Open to patients, caregivers & providers

Hosted by Carol Hunt & Raymond Hankins, Volunteer Support Group Leaders

RSVP to mckennafulton@mgakc.org

Greater Kansas City

Next Meeting— July 15, 2023

Quarterly on a Saturday | 10:00 AM-12:00 PM | Community Center D. at St. Joseph Medical Center, 1000 Carondelet Drive, Kansas City, MO

Light brunch is provided | Open to patients, caregivers & providers

RSVP: mckennafulton@mgakc.org

Kansas City Northland

Next Meeting— May 11, 2023

January-September, bi-monthly on a Thursday | 12:00-1:30 PM | Primrose Retirement Community, 8559 N. Line Creek Road, Kansas City, MO

Light lunch is provided | Open to patients, caregivers & providers

Hosted by Sandy Gardner, Volunteer Support Group Leader

RSVP: mckennafulton@mgakc.org

Mid-Missouri Support Group

Next Meeting— April 20, 2023

Quarterly on a Thursday | 5:30-7:00 PM | Daniel Boone Regional Library, 100 W. Broadway, Columbia, MO

Open to patients, caregivers & providers

Hosted by Jonni Jolliff, Volunteer Support Group Leader

RSVP: info@mgakc.org

NW Arkansas Support Group

Next Meeting— May 21, 2023

January-October, every other month on a Sunday | 2:30-4:30 PM | Springdale Public Library, 405 S. Pleasant Street, Springdale, AR

Open to patients, caregivers & providers

Hosted by Roger & Jan Huff, Volunteer Support Group Leaders

RSVP not required, however; the Huff's can be reached at jruff1@cox.net

The Skinny on MGA Support Groups

Springfield Support Group

Next Meeting– May 2, 2023

Quarterly on a Tuesday | 4:30-6:00 PM | East Sunshine Church of Christ, 3721 E. Sunshine St , Springfield, MO 65809

Open to patients, caregivers & providers

RSVP: info@mgakc.org

St. Joseph Support Group

Next Meeting– June 25, 2023

2:00-3:30 PM | Rolling Hills Library; Community Room, 1912 N Belt Hwy, St. Joseph, MO 64506

Open to patients, caregivers & providers

RSVP: donnasjmo@yahoo.com

St. Louis Support Group

Next Meeting– July 15, 2023

Quarterly on a Saturday | 10:00-11:30 AM | Glendale City Hall, Glendale MO

Light brunch provided | Open to patients, caregivers & providers

RSVP: info@mgakc.org

Topeka Area Support Group

Next Meeting– August 24, 2023

Quarterly on a Thursday | 6-7:30 PM | Topeka & Shawnee County Library 1515 SW 10th Ave, Topeka, KS

Open to patients, caregivers & providers

RSVP: mckennafulton@mgakc.org

Virtual Monthly Meet Up

Next Meeting– April 24, 2023

4th Monday of the month | 6:30-7:30 PM via Zoom

Open to patients, caregivers & providers

RSVP by registering for the webinar as posted

Virtual Youth Group

Next meeting– June 19, 2023

Meets quarterly on a Monday | 6:00 PM via Zoom

Open to youth who are diagnosed with myasthenia gravis and their parents

RSVP: allisonfoss@mgakc.org

Wichita Support Group

Next Meeting– May 6, 2023

Quarterly on a Saturday | 11:00-1:00 PM |

Open to patients, caregivers & providers

Hosted by Dana & Larry Paxson, Volunteer Support Group Leaders

RSVP: dkptiffany@gmail.com

Young Friends of the MGA– Kansas City

Next meeting– July 11, 2023 | 6pm | Zoom

Quarterly at various locations in Kansas City | 6:00-8:00 PM | LOCATION TBD

Open to patients who are generally in their 20s, 30s and 40s

RSVP: allisonfoss@mgakc.org

Young Friends of the MGA– St. Louis

Next Meeting– July 11, 2023 | 6pm | Zoom

Quarterly at various locations in St. Louis | 6:00-8:00 PM | LOCATION TBD

Open to patients who are generally in their 20s, 30s and 40s

RSVP: info@mgakc.org

Cruise with the MG Holistic Society

The MG Holistic Society is hosting a cruise for individuals with myasthenia gravis and their guests in December 2023.

Have you wanted to take a cruise? Do you want to meet other Myasthenia Gravis patients and their families? We invite you to come spend the holiday week with us. We will have a meet and greet for the MGHS Group. Participate in our cruise wide scavenger hunt for prizes during the first day at sea. Myasthenia Gravis patients are invited to our holistic support group at sea. Family and Friends are invited to our Vision Board Workshop just in time for the new year.

Please visit: www.thetravelcure.com or call 404-666-4484 to register for this cruise.

Email Dawn at dwarner@dreamvacations.com with any questions.



MYASTHENIA GRAVIS FRIENDS AND FAMILY CRUISE

Join us for our MG Friends and Family Cruise departing from Fort Lauderdale, FL

12/24 - Fort Lauderdale/ Meet & Greet
12/25 - At Sea - MG Scavenger hunt for prizes
12/26 - Labadee, Haiti
12/27 - Falmouth, Jamaica
12/28 - At Sea - Vision Board Workshop, Support Meeting
12/29 - Nassau, Bahamas
12/30 - Fort Lauderdale



See Group Information at www.TheTravelCure.com

404-666-4484

Passport is not required however recommend

Virtual Monthly Meet Ups continue

Our Virtual Monthly Meet Ups are still going strong and offer an at your fingertips educational experience. Led by our Virtual Meet Up Host, Sarah Bolton, our Virtual Monthly Meet Up generally meets the 4th Monday of the month from 6:30-7:30pm, you can also find recordings of most of them on our youtube channel (www.youtube.com/mgakc) to watch at your leisure. We have some great topics coming up that we want to share with you!



Sarah Bolton, Virtual Monthly Meet Up Host

Monday April 24, 2023— Clinical Trials with Angela Pontius of RA Ventures

Monday May 22, 2023— Seronegative Patient Panel with Bryan Bosch, Cheri Heitman, Celia Meyer & Christina Ramirez

Monday June 26, 2023— Updates from Immunovant

Monday July 24, 2023— Comorbidities & Myasthenia Gravis with Mamatha Pasnoor, MD



To sign up for a session, watch your email for a link to register. You must have a Zoom account to participate in these webinars. If we do not have your email on file, email us at info@mgakc.org to be added. Got a topic for a virtual monthly meet up you'd like to hear about? Let us know.

VYVGART[®]
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

An FDA-approved treatment

Talk to your
neurologist about
VYVGART

Find out more



VYVGART is a registered trademark of argenx.
For U.S. audiences only.
© 2022 argenx US-EFG-22-00080 V1 08/2022

Join us for the 12th Annual MGA Triple Crown Showdown

12th Annual MGA Triple Crown Showdown
8am | Sunday May 21, 2023
Town Center Plaza,
Leawood, KS
Patients registration FREE— contact
info@mgakc.org for code
www.mga5k.com
Patients can request a customized discount code to share with family and friends!



Scan to register!




Membership Donations

Carlos Rivera
Lyndsey Flihs
Virgil Wiltz
Wesley & Helen Stillan
Alan & Gail Still
Michael & Dorothy Eagan
Jackie & Scott Carroll
Derek & Nina Haverkamp
Kenneth & Lola Cook

Brodie Beck
Tom Vansaghi, PhD.
Don & Marilyn Sisson
Dan Cogan
Tim Hartney
Shannon Harris
April Zobel
Cindy Disque
Steve Bricker

Danielle Kempker
Mamatha Pasnoor, MD
Al & Kay Dimmitt
Richard Barohn, MD
Stephanie & Jeremy Hubers
Diana Wilmoth
Mazen Dimachkie, MD
Al & Kay Dimmitt

Thank you!



If you or a loved one has been diagnosed with generalized myasthenia gravis (gMG), the ExpandD Study may be an option. This clinical research study aims to evaluate the effects of an oral investigational medication in managing symptoms in adults with gMG.

TO BE ELIGIBLE FOR THIS STUDY, YOU MUST:

- Be at least 18 years of age
- Have a confirmed diagnosis of gMG
- Be on a stable dose of gMG medication
(only applies to those currently on gMG treatment)

To learn more, visit
ExpandTrial.com.

ExpandD
A FORWARD STUDY

ALEXION
AstraZeneca Rare Disease

Become a 2023 Member of the MYASTHENIA GRAVIS ASSOCIATION

*Help fund the tools
to fight myasthenia
gravis!*



-CONSIDER BECOMING
A MEMBER TODAY-

*Your financial support
helps to provide*

- new patient packets
- onsite clinic partnerships with neuromuscular specialists
- support & programming at one of our 16 support groups
- education & awareness events
- research
- 1-1 consultations

*programming that is
100% free to patients*

*your support is appreciated
beyond measure*



Myasthenia gravis (MG) has thrown a wrench into the lives of many.

Together, we can equip patients with the appropriate tools and resources they need on their journeys with MG.

Help the MGA nail down support for myasthenia gravis patients by becoming a member today!

Cut and enclose in envelope. Mail to MGA address below:

I want to support the MGA by becoming a 2023 member or making a contribution:

- \$25.00 Basic Membership
- \$63.00 63rd Anniversary Membership
- \$100.00 Sustaining Membership
- \$500.00 Patron Membership
- \$1,000.00 Lifetime Membership

\$ _____ In memory of: _____

\$ _____ In honor of: _____

Name _____

Address _____

City, State, Zip _____

Phone _____

Email _____

I am a: MG PATIENT RELATIVE FRIEND OTHER

MGA
2340 E. Meyer Blvd., Bld. 1, Suite 300A
Kansas City, MO, 64132

-Contributions may be tax deductible
-Make checks payable to:
Myasthenia Gravis Association

Myasthenia Gravis Association

2340 E. Meyer Blvd.
Building 1, Suite 300A
Kansas City, MO 64132
Phone: (816) 256-4100
Email: info@mgakc.org
www.mgakc.org

The Mission of the MGA

The Myasthenia Gravis Association (MGA) is dedicated to improving the quality of life for those who are affected by this autoimmune, neuromuscular disease, through awareness, education and patient services.



If you would like to be removed from or added to our mailing list, or if you have/will have an address change, please send a note to:

Myasthenia Gravis Association
2340 E. Meyer Blvd.
Building 1, Suite 300A
Kansas City, MO 64132

- OR -

Call us at: (816)-256-4100
Email us at: info@mgakc.org